BioXcel Therapeutics, Inc. last reported quarterly results on May 15, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $206,000 (+22.6% year over year) and diluted EPS of -$0.54. It usually reports 42–45 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 42–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 15, 2026
45 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
+22.6%
|
-13
-75.0%
|
-0.54
+64.0%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-54.2%
|
-31
-126.5%
|
-2.18
+57.7%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-89.1%
|
-19
-131.2%
|
-2.45
+25.8%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
-71.1%
|
-7
+72.9%
|
-1.50
+89.2%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
-37.2%
|
-14
+73.0%
|
-5.15
-199.4%
|
|
Jul 16, 2024
16 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 9, 2024
39 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Mar 12, 2024
72 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BTAIQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720893
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.